News
Lilly's Mounjaro demonstrates cardiovascular protection
US pharma major Eli Lilly has announced top-line results from SURPASS-CVOT, a first-of-its-kind head-to-head Phase III cardiovascular outcomes trial comparing two incretin therapies in adults with type 2 diabetes and established atherosclerotic cardiovascular disease.
A WOMAN who has lost 5.5 stone on Mounjaro in eight months has shared the advice everyone needs to hear. La Hauser, from the ...
Eli Lilly & Co.’s blockbuster diabetes drug Mounjaro was about as good at preventing heart attacks and strokes as its older ...
Eli Lilly and Company (NYSE:LLY) stock fell on Thursday morning after the pharmaceutical giant’s diabetes drug Mounjaro ...
A YOUNG woman has revealed that in 14 weeks, she has lost three stone on Mounjaro. But although Jess now feels “healthier” ...
Ozempic and Mounjaro are both very popular for weight loss at the minute, but there's one big difference between the two ...
A new study reports that mice shed about 20% of their body weight and saw their breast cancer tumors decrease after getting ...
A primary school teacher who weighed 24 stone and was terrified of fitting on a plane said jabs which helped her lose weight ...
Eli Lilly (LLY) recently announced promising findings from its SURPASS-CVOT trial, revealing Mounjaro's potential benefits over Trulicity in reducing cardiovascular events. Despite these positive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback